Immutep Ltd ADR (IMMP)
Immutep Ltd ADR is a depositary receipt listed on NASDAQ that represents common stock of Immutep Limited, a biotechnology company based in Sydney, Australia. The company focuses on developing LAG-3-related immunotherapies for cancer and autoimmune diseases. Its lead candidate is eftilagimod alfa, also known as efti or IMP321, which is being evaluated across multiple oncology settings. Immutep’s clinical pipeline includes programs in phase III, phase IIb, phase II, and phase I studies, with candidates such as TACTI-004 for first-line non-small cell lung cancer, TACTI-003 for first-line head and neck squamous cell carcinoma, AIPAC-003 for metastatic breast cancer, EFTISARC-NEO for soft tissue sarcoma, and IMP761 for autoimmune disease. The company also has research and development collaborations with Merck & Co., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. Founded in 1987, it was previously known as Prima BioMed Ltd before adopting the Immutep Limited name in 2017.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-IMMP
|
$0.61
|
53.5% Upside
|
Bargain
|
$1.50
|
275.9% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
September 2, 2026
|
-0.9x
|
0.7x
|
9.1x
|
50.69 M
|
-17.153 M
|
1.6%
|
97.1%
|
-5.5
|
—
|
74.2%
|
